{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:55:46Z","timestamp":1781661346750,"version":"3.54.5"},"reference-count":48,"publisher":"Norwegian Medical Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2011,2,4]]},"DOI":"10.4045\/tidsskr.09.0470","type":"journal-article","created":{"date-parts":[[2011,2,9]],"date-time":"2011-02-09T06:47:54Z","timestamp":1297234074000},"page":"244-7","source":"Crossref","is-referenced-by-count":9,"title":["Bisfosfonatbehandling av osteoporose og andre skjelettsykdommer"],"prefix":"10.4045","volume":"131","author":[{"given":"Unni","family":"Syversen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan I.","family":"Halse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"Aaseth J, Syversen U, F\u00f8rre \u00d8. Difosfonater \u2013 farmakologi og klinisk bruk. Tidsskr Nor L\u00e6geforen 1998; 118: 1064\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9531831&dopt=Abstract"},{"key":"ref=2","unstructured":"Syversen U, Halse JI. Behandling av osteoporose. Tidsskr Nor L\u00e6geforen 2003; 123: 2263-4. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14508549&dopt=Abstract"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006; 17: 1638\u2009\u2013\u200944. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16896510&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-006-0166-2","DOI":"10.1007\/s00198-006-0166-2"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38: 617\u2009\u2013\u200927. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16046206&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.bone.2005.05.003","DOI":"10.1016\/j.bone.2005.05.003"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Kavanagh KL, Guo K, Dunford JE et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006; 103: 7829\u2009\u2013\u200934. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16684881&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1073\/pnas.0601643103","DOI":"10.1073\/pnas.0601643103"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Russell RGG, Watts NB, Ebetino FH et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733\u2009\u2013\u200959. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18214569&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-007-0540-8","DOI":"10.1007\/s00198-007-0540-8"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs. Bone 2006; 39: 443\u2009\u2013\u200952. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16627025&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.bone.2006.02.060","DOI":"10.1016\/j.bone.2006.02.060"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis\u2013optimizing efficacy in clinical practice. Clin Interv Aging 2008; 3: 279\u2009\u2013\u200997. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18686751&dopt=Abstract","DOI":"10.2147\/CIA.S2134"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Black DM, Cummings SR, Karpf DB et al; Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535\u2009\u2013\u200941. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8950879&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(96)07088-2","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077\u2009\u2013\u200982. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9875874&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jama.280.24.2077","DOI":"10.1001\/jama.280.24.2077"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Harris ST, Watts NB, Genant HK et al; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344\u2009\u2013\u200952. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10527181&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jama.282.14.1344","DOI":"10.1001\/jama.282.14.1344"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Reginster J, Minne HW, Sorensen OH et al; Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83\u2009\u2013\u200991. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10663363&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s001980050010","DOI":"10.1007\/s001980050010"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Chesnut CH III, Skag A, Christiansen C et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15231010&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1359\/JBMR.040325","DOI":"10.1359\/JBMR.040325"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Black DM, Delmas PD, Eastell R et al. Once-yearly zoledonic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17476007&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa067312","DOI":"10.1056\/NEJMoa067312"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333\u2009\u2013\u200940. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11172164&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJM200102013440503","DOI":"10.1056\/NEJM200102013440503"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P et al. Alendronate for the treatment of osteoporosis in men N Engl J Med 2000. N Engl J Med 343: 604\u2009\u2013\u2009610.","DOI":"10.1056\/NEJM200008313430902"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Ringe JD, Faber H, Farahmand P et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26: 427\u2009\u2013\u200931. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16001181&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00296-005-0004-4","DOI":"10.1007\/s00296-005-0004-4"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Saag KG, Emkey R, Schnitzer TJ et al; Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9682041&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJM199807303390502","DOI":"10.1056\/NEJM199807303390502"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838\u2009\u2013\u200946. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16729277&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/art.21918","DOI":"10.1002\/art.21918"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al. The Horizon recurrent fracture trial. Zoledronic acid and clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: nihpa40967.","DOI":"10.1056\/NEJMoa074941"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Reid DM, Hosking D, Kendler D et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS \u2013 international. Clin Drug Investig 2006; 26: 63\u2009\u2013\u200974. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17163237&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00044011-200626020-00002","DOI":"10.2165\/00044011-200626020-00002"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Cramer JA, Gold DT, Silverman SL et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023\u2009\u2013\u200931. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17308956&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-006-0322-8","DOI":"10.1007\/s00198-006-0322-8"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16901023&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4065\/81.8.1013","DOI":"10.4065\/81.8.1013"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Jude EB, Selby PL, Burgess J et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double blind randomised controlled trial. Diabetologia 2001; 44: 2032\u2009\u2013\u20097. Crossref: http:\/\/dx.doi.org\/10.1007\/s001250100008","DOI":"10.1007\/s001250100008"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Stewart GW, Brunet ME, Manning MR et al. Treatment of stress fractures in athletes with intravenous pamidronate. Clin J Sport Med 2005; 15: 92\u2009\u2013\u20094. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15782053&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/01.jsm.0000152716.06883.e0","DOI":"10.1097\/01.jsm.0000152716.06883.e0"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Ringe JD, Dorst A, Faber H. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 2005; 16: 2063\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16228105&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-005-2001-6","DOI":"10.1007\/s00198-005-2001-6"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Siris ES, Lyles KW, Singer FR et al. Medical management of Paget\u2019s disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 2006; 21 (suppl 2): P94\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17229018&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1359\/jbmr.06s218","DOI":"10.1359\/jbmr.06s218"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; nr. 3: CD003474. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16034900&dopt=Abstract","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Lacy MQ, Dispenzieri A, Gertz MA et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047\u2009\u2013\u200953. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16901028&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4065\/81.8.1047","DOI":"10.4065\/81.8.1047"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Yuen KK, Shelley M, Sze WM et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; nr. 4: CD006250. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17054286&dopt=Abstract","DOI":"10.1002\/14651858.CD006250"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9 (suppl 4): 3\u2009\u2013\u200913. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15459425&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1634\/theoncologist.9-90004-3","DOI":"10.1634\/theoncologist.9-90004-3"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Schippinger W et al; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679\u2009\u2013\u200991. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19213681&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa0806285","DOI":"10.1056\/NEJMoa0806285"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Trabulus S, Altiparmak MR, Apaydin S et al. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant Proc 2008; 40: 160\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18261575&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.transproceed.2007.12.001","DOI":"10.1016\/j.transproceed.2007.12.001"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010; 86: 421\u2009\u2013\u200935. . PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20407762&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00223-010-9364-1","DOI":"10.1007\/s00223-010-9364-1"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Bergner R, Diel IJ, Henrich D et al. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006; 29: 534\u2009\u2013\u200940. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17068390&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1159\/000096056","DOI":"10.1159\/000096056"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Guarneri V, Donati S, Nicolini M et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist 2005; 10: 842\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16314295&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1634\/theoncologist.10-10-842","DOI":"10.1634\/theoncologist.10-10-842"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen HT, Christensen S, Mehnert F et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336: 813\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18334527&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/bmj.39507.551644.BE","DOI":"10.1136\/bmj.39507.551644.BE"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Woo S-B, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753\u2009\u2013\u200961. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16702591&dopt=Abstract","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"ref=39","unstructured":"L\u00f8kken P, Skoglund LA, Skjelbred P. Kjeveosteonekrose ved bisfosfonatbehandling. Tidsskr Nor L\u00e6geforen 2007; 127: 1945-7. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17700737&dopt=Abstract"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009; 122 (suppl): S33\u2009\u2013\u200945. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19187811&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.amjmed.2008.12.005","DOI":"10.1016\/j.amjmed.2008.12.005"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Khosla S, Burr D, Cauley J et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479\u2009\u2013\u200991. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17663640&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1359\/jbmr.0707onj","DOI":"10.1359\/jbmr.0707onj"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Liberman UA. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. Drugs Aging 2006; 23: 289\u2009\u2013\u200998. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16732688&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00002512-200623040-00002","DOI":"10.2165\/00002512-200623040-00002"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Black DM, Schwarts AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927\u2009\u2013\u200938. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17190893&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jama.296.24.2927","DOI":"10.1001\/jama.296.24.2927"},{"key":"ref=44","unstructured":"Kristiansen IS, Falch JA, Andersen L et al. Bruk av alendronat ved osteoporose \u2013 er det kostnadseffektivt? Tidsskr Nor L\u00e6geforen 1997; 117: 2619\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9324817&dopt=Abstract"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Stevenson M, Jones ML, De Nigris E et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9: 1\u2009\u2013\u2009160. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15929857&dopt=Abstract","DOI":"10.3310\/hta9220"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Sen SS et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries\u2013an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18: 1047\u2009\u2013\u200961. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17333449&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-007-0349-5","DOI":"10.1007\/s00198-007-0349-5"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Schousboe JT, Ensrud KE, Nyman JA et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005; 53: 1697\u2009\u2013\u2009704. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16181168&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1532-5415.2005.53504.x","DOI":"10.1111\/j.1532-5415.2005.53504.x"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranny A, Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Syst Rev 2008; nr. 1, CD: 001155.","DOI":"10.1002\/14651858.CD001155.pub2"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:35:20Z","timestamp":1781660120000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2011\/02\/oversiktsartikkel\/bisfosfonatbehandling-av-osteoporose-og-andre-skjelettsykdommer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,4]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2,4]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.09.0470","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,4]]}}}